Altimmune Inc (NASDAQ: ALT) closed a $75 million registered direct offering of common stock, issuing 17,045,454 shares to a new fundamental institutional investor. The company plans to use the net proceeds for its Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and general corporate purposes. The offering strengthens Altimmune's balance sheet as it advances its lead candidate pemvidutide, a dual glucagon/GLP-1 agonist that received FDA Breakthrough Therapy Designation.

Altimmune, Inc. closed a $75 million registered direct offering of common stock and pre-funded warrants to strengthen its balance sheet. The company plans to use proceeds for its Phase 3 trial of pemvidutide, a dual glucagon/GLP-1 agonist for MASH treatment, which recently received FDA Breakthrough Therapy Designation.

The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.

Altimmune, Inc. announced a registered direct offering of approximately 17 million shares to raise $75 million in gross proceeds. The company plans to use the funds to prepare for its Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) using its lead candidate pemvidutide, a glucagon/GLP-1 dual agonist that recently received FDA Breakthrough Therapy Designation and demonstrated positive Phase 2b results.

The global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.

Faruqi & Faruqi is investigating potential claims against Altimmune after its stock price dropped 53.2% following disappointing Phase 2b MASH trial results for Pemvidutide, where statistical significance was not achieved.

A class action lawsuit has been filed against Altimmune, alleging the company made false and misleading statements about its Pemvidutide trial results in the MASH Phase 2b study, with claims of overstated efficacy and downplaying of statistical significance.

Rosen Law Firm alerts Altimmune investors about a securities class action lawsuit regarding misleading information about the IMPACT Phase 2b MASH trial results, with an October 6, 2025 deadline to join the action.

The Schall Law Firm is pursuing a class action lawsuit against Altimmune for allegedly making false and misleading statements about its drug candidate Pemvidutide, which failed to achieve statistically significant results in its Phase 2B MASH trial.

A class action lawsuit has been filed against Altimmune, alleging the company made false and misleading statements about its Pemvidutide trial results and potential regulatory success during the period of August 10, 2023 to June 25, 2025.

Altimmune faces a class action lawsuit alleging false and misleading statements about its Pemvidutide drug trial, which did not demonstrate statistically significant results in its Phase 2B MASH trial.

Bragar Eagel & Squire, P.C. announced a class action lawsuit against Altimmune regarding its MASH trial results, with investors having until October 6th, 2025 to apply as lead plaintiff in the lawsuit.